Alpha-thalassemia mental retardation X-linked syndrome protein (ATRX)

Alpha-thalassemia mental retardation X-linked syndrome protein (ATRX) is a multi-domain chromatin remodeler and transcriptional regulator, essential for the maintenance of chromatin structure, genomic stability, DNA repair, and gene regulation. ATRX forms a complex with DAXX to deposit the histone variant H3.3 into specific chromatin regions, particularly at telomeres and repetitive sequences, promoting transcriptional silencing and DNA integrity. Mutations or loss of ATRX disrupt these processes, resulting in syndromic intellectual disability (ATR-X syndrome) and contributing to tumorigenesis, especially in gliomas and neuroendocrine cancers. The protein contains ATPase and ADD (ATRX-DNMT3-DNMT3L) domains with high DNA and histone-binding capacity. It plays a pivotal role in normal neuronal development, cell cycle progression, DNA homologous recombination repair, and cellular response to replication stress. ATRX is a subject of intense research for cancer biomarkers and potential therapeutic targeting, though no specific drugs currently act on it. Loss or mutation of ATRX often serves as a biomarker for disease classification, prognosis, and therapy response, reflecting its central importance in genome integrity and chromatin dynamics.

Other names

Alpha-thalassemia mental retardation X-linked proteinX-linked helicase IIDeath-domain-associated protein binding partner (in function with DAXX)ATR-X syndrome protein

For future drugs: theoretical mechanisms would include modulation of chromatin accessibility, restoration of homologous recombination, interference with ATRX/DAXX/H3.3 nucleosome assembly, or restoration of telomeric silencing. Currently, ATRX status predicts response to DNA damage and replication stress-targeting therapies (e.g., PARP inhibitors, alkylating agents in glioma).